JP6944925B2 - 組織浸潤ｎｋ細胞を検出する方法 - Google Patents

組織浸潤ｎｋ細胞を検出する方法 Download PDF

Info

Publication number
JP6944925B2
JP6944925B2 JP2018503182A JP2018503182A JP6944925B2 JP 6944925 B2 JP6944925 B2 JP 6944925B2 JP 2018503182 A JP2018503182 A JP 2018503182A JP 2018503182 A JP2018503182 A JP 2018503182A JP 6944925 B2 JP6944925 B2 JP 6944925B2
Authority
JP
Japan
Prior art keywords
cells
antibody
nkp46
sample
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018503182A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528410A5 (https=
JP2018528410A (ja
Inventor
ナディア・アンセリズ
セシル・ボナフー
アルノー・デュジャルダン
カリーヌ・パトゥレル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of JP2018528410A publication Critical patent/JP2018528410A/ja
Publication of JP2018528410A5 publication Critical patent/JP2018528410A5/ja
Application granted granted Critical
Publication of JP6944925B2 publication Critical patent/JP6944925B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018503182A 2015-07-24 2016-07-04 組織浸潤ｎｋ細胞を検出する方法 Active JP6944925B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562196409P 2015-07-24 2015-07-24
US62/196,409 2015-07-24
PCT/EP2016/065653 WO2017016805A1 (en) 2015-07-24 2016-07-04 Methods for detecting tissue infiltrating nk cells

Publications (3)

Publication Number Publication Date
JP2018528410A JP2018528410A (ja) 2018-09-27
JP2018528410A5 JP2018528410A5 (https=) 2019-07-11
JP6944925B2 true JP6944925B2 (ja) 2021-10-06

Family

ID=56368945

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018503182A Active JP6944925B2 (ja) 2015-07-24 2016-07-04 組織浸潤ｎｋ細胞を検出する方法

Country Status (8)

Country Link
US (1) US10736963B2 (https=)
EP (1) EP3325967B1 (https=)
JP (1) JP6944925B2 (https=)
KR (1) KR102554507B1 (https=)
CN (1) CN107850596B (https=)
AU (1) AU2016299166B2 (https=)
CA (1) CA2990520C (https=)
WO (1) WO2017016805A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6822849B2 (ja) * 2014-06-27 2021-01-27 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的ＮＫｐ４６結合タンパク質
IL250579B2 (en) 2014-10-10 2023-05-01 Innate Pharma blocking cd73
AU2016299166B2 (en) 2015-07-24 2022-03-31 Innate Pharma Methods for detecting tissue infiltrating NK cells
SG11202111106WA (en) 2019-04-23 2021-11-29 Innate Pharma Cd73 blocking antibodies
CN110187107A (zh) * 2019-04-26 2019-08-30 温州医科大学 一种基于肿瘤组织浸润免疫细胞特征建立的结直肠癌预后评估装置及方法
CN110862963B (zh) * 2019-11-27 2021-08-27 沣潮医药科技（上海）有限公司 蜕膜nk细胞及其细胞亚群在制备不孕不育相关疾病治疗药物中的用途
US20230348854A1 (en) * 2020-05-08 2023-11-02 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Chimeric antigen receptors (cars) targeting natural killer cells
CN116125078A (zh) * 2023-01-17 2023-05-16 复旦大学附属中山医院 一种检测ctc抵抗nk细胞杀伤的试剂盒及其应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE423848T1 (de) * 1999-11-15 2009-03-15 Innate Pharma Auslösender rezeptor der an der natürlichen cytotoxizität der menschlichen natürlichen killerzellen (natural killer cells) beteiligt ist und antikörper die diesen rezeptor identifizieren
US6979546B2 (en) 1999-11-15 2005-12-27 Universita Di Genova Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same
EP1219637A1 (en) 2000-12-27 2002-07-03 Innate Pharma Polypeptides having a triggering NK activity and biological applications
CA2454185A1 (en) 2001-07-19 2003-01-30 Innate Pharma Ntb-a, a surface molecule involved in natural killer cells activity
WO2004056392A1 (en) 2002-12-23 2004-07-08 Innate Pharma Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same
US7803376B2 (en) 2003-07-24 2010-09-28 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
WO2005105848A1 (en) 2004-04-30 2005-11-10 Innate Pharma Compositions and methods for enhancing nk cell activity
WO2005105849A1 (en) 2004-04-30 2005-11-10 Innate Pharma Compositions and methods for treating proliferative disorders such as nk-type ldgl
EP2287195B1 (en) 2004-07-01 2019-05-15 Novo Nordisk A/S Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
ATE548389T1 (de) 2004-08-03 2012-03-15 Innate Pharma Therapeutische und diagnostische verfahren und zusammensetzungen zum targeting von 4ig-b7-h3 und dem entsprechenden nk-zellen-rezeptor
AU2005321017B2 (en) 2004-12-28 2011-02-24 Innate Pharma S.A. Monoclonal antibodies against NKG2A
CN101103043A (zh) 2005-01-06 2008-01-09 诺和诺德公司 Kir结合剂和使用其的方法
EP3072522B1 (en) 2005-01-06 2019-04-24 Novo Nordisk A/S Anti-kir combination treatments and methods
US20080196111A1 (en) 2005-03-18 2008-08-14 Innate Pharma S.A. Expression Vectors and Methods for Obtaining Nk Cell Specific Expression
AU2006301163B2 (en) 2005-10-14 2012-02-23 Innate Pharma Compositions and methods for treating proliferative disorders
WO2007103901A2 (en) * 2006-03-06 2007-09-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer
CN106963947A (zh) 2010-11-22 2017-07-21 伊纳特医药股份有限公司 Nk细胞调节治疗和用于治疗血液恶性疾病的方法
SG10201603962TA (en) 2011-05-25 2016-07-28 Innate Pharma Sa Anti-kir antibodies for the treatment of inflammatory disorders
US20140234342A1 (en) 2011-06-21 2014-08-21 Innate Pharma Nkp46-mediated nk cell tuning
EP2812027A1 (en) 2012-02-07 2014-12-17 Innate Pharma Mica binding agents
EP2841563B1 (en) 2012-04-24 2019-06-12 Dan S. Kaufman Method for developing natural killer cells from stem cells
EP2687852A1 (en) * 2012-07-17 2014-01-22 Laboratorios Del. Dr. Esteve, S.A. Method for diagnosing and treating chronic fatigue syndrome
US9789182B2 (en) 2012-10-23 2017-10-17 Bristol-Myers Squibb Company Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
DK2956482T3 (en) 2013-02-14 2017-10-16 Innate Pharma TREATMENT OF PERFECT T cell lymphoma
DK2958941T3 (da) 2013-02-20 2019-06-24 Innate Pharma Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom
JP6822849B2 (ja) 2014-06-27 2021-01-27 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的ＮＫｐ４６結合タンパク質
CA2952532A1 (en) 2014-06-27 2015-12-30 Innate Pharma Multispecific antigen binding proteins
JP2017532025A (ja) 2014-09-10 2017-11-02 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 交差反応性ｓｉｇｌｅｃ抗体
CA2959463A1 (en) 2014-09-16 2016-03-24 Innate Pharma Treatment regimens using anti-nkg2a antibodies
SMT202000562T1 (it) 2014-09-16 2020-11-10 Innate Pharma Neutralizzazionne delle vie inibitorie nei linfociti
EP3209687A1 (en) 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
US9767555B2 (en) 2015-01-05 2017-09-19 Case Western Reserve University Disease characterization from fused pathology and radiology data
WO2016207278A1 (en) 2015-06-23 2016-12-29 Innate Pharma Multispecific nk engager proteins
DK3313876T3 (da) 2015-06-23 2025-04-22 Innate Pharma Multispecifikke antigenbindende proteiner
AU2016299166B2 (en) 2015-07-24 2022-03-31 Innate Pharma Methods for detecting tissue infiltrating NK cells
CA3004972A1 (en) 2015-11-17 2017-05-26 Innate Pharma Siglec-10 antibodies
CN115925933A (zh) 2015-12-28 2023-04-07 依奈特制药公司 NKp46结合蛋白的可变区
CA3012055A1 (en) 2016-01-21 2017-07-27 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
WO2017153433A1 (en) 2016-03-08 2017-09-14 Innate Pharma Siglec neutralizing antibodies
RU2018128215A (ru) 2016-03-15 2020-04-15 Иннейт Фарма Антитела против mica
WO2018115262A1 (en) 2016-12-23 2018-06-28 Innate Pharma Heterodimeric antigen binding proteins
WO2018138032A2 (en) 2017-01-24 2018-08-02 Innate Pharma NKp46 BINDING AGENTS

Also Published As

Publication number Publication date
EP3325967A1 (en) 2018-05-30
CA2990520A1 (en) 2017-02-02
EP3325967B1 (en) 2019-12-04
JP2018528410A (ja) 2018-09-27
US20180369373A1 (en) 2018-12-27
CN107850596B (zh) 2020-12-04
CA2990520C (en) 2023-06-27
US10736963B2 (en) 2020-08-11
AU2016299166A1 (en) 2018-02-15
CN107850596A (zh) 2018-03-27
KR20180066027A (ko) 2018-06-18
KR102554507B1 (ko) 2023-07-11
WO2017016805A1 (en) 2017-02-02
AU2016299166B2 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
JP6944925B2 (ja) 組織浸潤ｎｋ細胞を検出する方法
JP6666905B2 (ja) Ｐｄ−ｌ１抗体及びその使用
JP6636016B2 (ja) 抗ｂ７−ｈ３抗体及びその診断用途
JP2017532025A (ja) 交差反応性ｓｉｇｌｅｃ抗体
EP2334703B1 (en) Compositions and methods for detecting tlr3
EP3560957A2 (en) Antibody binding specifically to cd66c and use thereof
JP2020532572A (ja) 癌の診断に有用な抗体
US20240117042A1 (en) Immunohistochemistry methods and kir3dl2-specific reagents
JP7821779B2 (ja) 抗体を使用した細胞表面ｍｉｃａ及びｍｉｃｂの検出
CN115403670B (zh) 抗cd40抗体及其用途

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190606

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210603

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210818

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210913

R150 Certificate of patent or registration of utility model

Ref document number: 6944925

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250